The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
SageTech Medical announces distribution agreement with Draeger UK
Jun 9, 2023
SageTech Medical is pleased to announce the signing of a distribution agreement with Draeger Medical UK Ltd.
The agreement paves the way for Draeger UK’s NHS Supply Chain customers to purchase SageTech’s leading anaesthetic gas capture machine.
SageTech Medical launched the SID-Dock waste anaesthetic gas capture machine in January 2023, which is a UKCA Marked, Class 1 Medical Device for the safe and sustainable capture of volatile anaesthetic gases, addressing the unmet need to prevent 2% of NHS carbon emissions each year.
Iain Menneer, CEO of SageTech Medical said “This agreement makes it simple for our mutual NHS customers to gain access to our innovative gas capture technology. The agreement aims to accelerate our mission to help healthcare providers prevent the significant pollution caused from the use of these vital anaesthetic gases and reduce the raw materials used and associated carbon emission in their virgin manufacture”.
Matthew Bedford, Managing Director Sales & Service, Draeger UK & Ireland said “We are very pleased to enable Draeger’s UK customers to access SageTech’s gas capture solution to help in the ongoing challenge of reducing the potential environmental impact from waste anaesthetic gases. We have enjoyed our collaboration with the SageTech Medical team and look forward to this agreement supporting our customers to make significant steps towards Net Zero”.
Notes:
SageTech Medical Equipment Ltd was started in 2015 to develop innovative solutions to environmental problems, initially in human and veterinary healthcare. SageTech Medical launched its solution in January 2023 to prevent the release of millions of tonnes of CO2 equivalents of waste anaesthetic into the atmosphere each year from hospitals around the world.
Dräger is an international leader in the fields of medical and safety technology. Since 1889, Dräger products protect, support and save lives. The Dräger Group is currently present in over 190 countries and has more than 16,000 employees worldwide.
Huge congratulations to all those selected as finalists for the Annual EISA Awards 2023. Winners will be announced at the House of Lords on Thursday 22nd June.
Thank you to everyone who entered this year. Our judges saw more than 100 entries and the standard of competition has been extremely impressive. Best of luck to all those shortlisted!
Best EIS Investee Company Sponsored by Guinness Ventures
Integrated Graphene Medwise AI
Q-Bot Novai
GenoME Diagnostics Scan.com
Also...
Sagetech just finishing a crowd fund that values it approx £17M, so our fair value of $0.9M is bang on.
Sargi the CFO, is the chap who has never sold a single share received via SBC.
Has held on to the lot, while the other 2 have always sold a chunk.
June 22 valuation was £29.2M when PDSB was worth £4M.
April 23 trading update talked of a sig uplift in NAV (not PDSB)
As of Friday PDSB worth £10M+
So NAV £35M without the new valuations.
SP 70p giving M Cap of £16M.
Go figure!
The results posted last night were pretty staggering. They confirm 100% the mode of action for PDSB.
Keytruda is the biggest selling drug in the world doing approx $25B of sales a year.
Add PDS0101 to Keytruda and it is twice as effective and patients are living twice as long (and still going) with less side effects.
If the PDSB platform works across other cancers with Keytruda then do the maths.
MRK is one of the richest companies in the the Bio world and won't want to lose PDSB.
In measuring the efficacy of PDS0101 in combination with KEYTRUDA®, the abstract highlights the following interim data:
Estimated 12-month overall survival rate was 87.1%. Published results are 36-50% with approved ICIs used alone*.
Median progression-free survival was 10.4 months (95% CI 4.2, 15.3). Published results are median PFS of 2-3 months for approved ICIs when used as monotherapy in patients with similar PD-L1 levels*.
A disease control rate (disease stabilization or tumor shrinkage) of 70.6% (24/34)
Confirmed and unconfirmed objective response rate was 41.2% (14/34 patients), which is identical to the preliminary response rate data PDS Biotech previously reported at ASCO 2022 (7/17 patients). To date these responses have been confirmed in nine of the 34 patients (26.5%), including one complete response.
15/34 patients (44.1%) had stable disease.
9/34 patients (26.5%) had progressive disease.
4/48 (8.3%) of patients had a Grade 3 treatment-related adverse event (TRAE). No Grade 4 or higher TRAEs were observed.
Highest volume for months.
Sp has been going up since they released the 100 page chapter and verse from LG.
It was pretty damning stuff for LG and perhaps some funds have taken counsel and come up with the same view we did.
LG reputation and shady business practice will be on show for all to see if this goes to court.
I also think we could go after Nielson as they folded under pressure from LG, so they may bring pressure to bear on LG to settle.
Worldquant closed 0.01 of their long term short yesterday.
All Tremor investors should go to 476 on the list and read from point 41 onwards.
Black and white explanation of how they tried and succeeded in fooking us from Aug/Sept 21 onwards.
I can't see how they can risk this going to court.
Safe to assume we got the full $10M owed to us, plus interest and costs?
The fact that Alphonso/Lg have agreed to pay must put them on the back foot for the rest of the case?
Below is the original claim from 2 years ago.
In January 2021, Alphonso publicly revealed the identity of the acquirer: LG
Electronics, Inc. (“LG”). After the public announcement, Alphonso terminated the Strategic
Partnership Agreement, effective May 14, 2021. Rather than cooperating to wind down the
years-long partnership in a responsible and professional manner, Alphonso has engaged in
numerous material breaches of the parties’ contracts and other tortious conduct, with the
apparent aim of competing unfairly against Tremor. Among other things, Alphonso has
misused Tremor’s confidential information in an attempt to steal Tremor’s clients, has recruited
Tremor’s employees and has refused to remit over
ten million dollars of the money Tremor advanced to Alphonso and that Alphonso has a clear duty to repay.
I have only read the judgement once but this is my take
LG sought to have the claims against it thrown out on jurisdiction grounds on the basis that even if they did what it is alleged by the Plaintiff they did those actions were taken in Korea and not in New York. LG weren't a party to the contracts and there could be no contractual claims against them.
Their lack of jurisdiction claims were thrown out because it was at least arguable they were part of a conspiracy to breach contract by Alphonso that the claims should be allowed to proceed to be determined on the facts.
An equitable claim of unjust enrichment by the Plaintiff was a make weight claim and did not add any value to the contractual/tort claims that it was either conceded or will be thrown out in the judgement. During argument it transpired that recently (last 2 weeks) Alphonso/LG paid TRMR the loan made to alphonso by it and presumably interest & costs.
I haven't read any further than the judgement but it would appear that there is a timetable for a hearing for the claimants claim to summary judgement which timetable might need to be adjusted to accommodate a couple of depositions that still need to take place.
That's my take on it
Far more interesting than the Lynch proceedings so lets discuss Tremor.
Judge coming out in our favour on a number of questions.
New Doc's Loaded & Very Interesting
https://iapps.courts.state.ny.us/nyscef/DocumentList?docketId=j/MKa5jKQOiZ2rhRcKfwfw==&PageNum=7&narrow=
Looks like everyone else has survived the first qtr intact.
2nd qtr guidance +5/10% and then a much better improvement/seasonality into the 2nd half.
Any chance of us joining the gang again or a pos for the 4th time?!
During the Coronation weekend it was a Privilege and Honour for #MKA to meet His Excellency the President of Malawi Lazarus Chakwera,as well as the Minister of Foreign Affairs Hon Nancy Tembo, High Commissioner Thomas Bisika and Secretary to the President & Cabinet Mrs Colleen Zamba and discuss the Songwe Rare Earth Mining Project #MKA #RareEarths
A positive tweet. I have asked why they can't update their shareholders as the failed completely in the recent results!
@USEmbassyLLW
Buyer finally showing their hand?
Anyone still holding apart from me?
Serves them right.
They fooked us and now they are getting fooked themselves.
With any luck one of the Alphonso players will get his own back by handing over some info to Tremors lawyers.
I don't think the CFO as ever sold any of his options when they vest.
Always taken that as a positive.
Carve up begins. Bacthera buys 4D’s manufacturing site in Léon
hTTps://legaldealmaker.com/baker-advises-bacthera-of-4d-pharmas-plc-site-acquisition/
Loaf: Paying. Classic Tosca
Joint deal with Mithaq and another PE fund. 500p sufficient for Schroders and news corp.
They will then refi part of their equity post deal with debt plus the Alphonso settlement
And re sell the business for the equavkent of 1000p-1200p in 3 years time.
With the leverage they will easily make 4x on their equity